RADIATION THERAPY ONCOLOGY GROUP

放射治疗肿瘤学组

• 批准号: 3558462
• 负责人: CHRISTOPHER T COUGHLIN
• 金额: $ 6.81万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-08-01 至 1989-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558462
• 关键词: antineoplastics; bone neoplasms; brain neoplasms; breast neoplasms; bronchogenic carcinoma; carmustine; cis platinum compound; combination cancer therapy; combination chemotherapy; computer assisted patient care; cooperative study; fluorouracil; glioma; head /neck neoplasm; human subject; human therapy evaluation; liver neoplasms; lung neoplasms; microwave radiation; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer thermotherapy; oral pharyngeal neoplasm; prostate neoplasms; squamous cell carcinoma

The primary objective of this proposal is to obtain funding that would insure the continued participation of Dartmouth-Hitchcock Medical Center in a cooperative clinical investigation group, specifically the Radiation Therapy Oncology Group. The ultimate goal of the Group's interactions is to improve the use of radiation therapy for the treatment of patients with malignant disease. All clinical trials sponsored by the Radiation Therapy Oncology Group are scientifically developed by members of the Group and then closely scrutinized for compliance within prescribed standards. The Group is full supported by the National Cancer Institute. Another objective is the development of new protocols by the faculty of Dartmouth-Hitchcock Medical Center. The Center has substantial experience in the development of new innovative therapies for the treatment of patients with malignant disease. Many of these programs are amenable to cooperative group study and efforts will be made to incorporate these into the Radiation Therapy Oncology Group's future studies. A third objective is the enhancement of communication between Dartmouth-Hitchcock Medical Center and other institutions and their investigators, thus insuring state-of-the-art treatment for patients with malignant disease. Finally, members of Dartmouth-Hitchcock Medical Center's faculty will actively participate in the Group's scientific and administrative functions by serving as members of various Group committees such as the Modality Subcommittees, the Protocol Site Committee, and the Standing Administrative Committees.

本提案的主要目标是获得资金， 将确保达特茅斯-希区柯克继续参与 医学中心临床合作研究组， 特别是放射治疗肿瘤组 最终 该小组的互动目标是改善辐射的使用 用于治疗恶性疾病患者的疗法。 所有 由放射治疗肿瘤学组申办的临床试验 由本集团成员科学开发， 严格审查是否符合规定的标准。 该小组得到了国家癌症研究所的全力支持。 另一个目标是制定新的协议， 达特茅斯-希区柯克医学中心 该中心已 在新的创新发展的丰富经验 用于治疗恶性疾病患者的疗法。 这些课程中有许多适合于合作小组学习 并将努力将这些纳入辐射中 肿瘤治疗组的未来研究。 第三个目标是加强 达特茅斯-希区柯克医疗中心和其他机构， 他们的研究人员，从而确保国家的最先进的治疗， 恶性疾病患者。 最后，达特茅斯-希区柯克医疗中心的成员 教师将积极参与该集团的科学和 作为各集团成员， 方式小组委员会、《议定书》 现场委员会和常设行政委员会。